Agency / Source: Report Buyer Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Report Says Global Alcohol Treatment Market will Hit $304m by 2016 - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the global market for the treatment of alcohol dependence will reach $304m by 2016
New Report Says Global Alcohol Treatment Market will Hit $304m by 2016

 

PRZOOM - /newswire/ - London, United Kingdom, 2008/03/18 - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the global market for the treatment of alcohol dependence will reach $304m by 2016.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the global market for the treatment of alcohol dependence will grow at a compound annual growth rate of 13.5% from 2006 to reach $304m by 2016

The report, "Pipeline Insight - Substance Dependence - Part II (Alcohol)" finds that the main factors influencing the market will be the continued uptake of existing brands and the launch of two opioid antagonists. It reports that opioid eantagonists are the most prevalent drug class in late-stage development and include two reformulations of naltrexone.

Analysts state that the current alcohol dependence pipeline is weak and lacking in innovation, leaving market opportunity for new therapies. Additionally, they say that the efficacy of currently marketed pharmaceutical products is limited, displaying poor medication compliance rate in alcohol-dependent patients. This leads them to predict that pipeline drugs that possess the potential to improve patient compliance can expect to receive a strong uptake.

Authors of the report say that the alcohol dependence market requires a shift in public perception. They say alcohol dependence should no longer be seen as a behavioral disorder, but as a treatable medical condition. They also benchmark key late-stage anti- alcohol dependence compounds against the current market leader.

The study assesses the seven major markets and contains total sales forecasts of key late-stage pipeline drugs. It also examines their clinical and commercial potential. It forecasts key late-stage pipeline drugs revenues to 2016

"Pipeline Insight - Substance Dependence - Part II (Alcohol)" is available from Report Buyer. For more information, see website.

Report Buyer product ID: DAT09505

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information. The website now carries over 44,000 business information products, including market reports, studies, books and events. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Report Buyer Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Report Says Global Alcohol Treatment Market will Hit $304m by 2016

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Urmila Doraswami 
+44 (0) 20 7060 7474 press[.]reportbuyer.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Report Buyer Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Report Buyer Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today